135 related articles for article (PubMed ID: 28915956)
1. Dual inhibition of P-glycoprotein and midkine may increase therapeutic effects of anticancer drugs.
Aynacıoğlu AŞ; Bilir A; Kadomatsu K
Med Hypotheses; 2017 Sep; 107():26-28. PubMed ID: 28915956
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
3. Reversal of multidrug resistance of tumor cells.
Szabó D; Keyzer H; Kaiser HE; Molnár J
Anticancer Res; 2000; 20(6B):4261-74. PubMed ID: 11205256
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
5. Relevance of multidrug resistance in the age of targeted therapy.
Türk D; Szakács G
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
[TBL] [Abstract][Full Text] [Related]
6. Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles.
Lopes-Rodrigues V; Di Luca A; Mleczko J; Meleady P; Henry M; Pesic M; Cabrera D; van Liempd S; Lima RT; O'Connor R; Falcon-Perez JM; Vasconcelos MH
Sci Rep; 2017 Mar; 7():44541. PubMed ID: 28303926
[TBL] [Abstract][Full Text] [Related]
7. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
Modok S; Mellor HR; Callaghan R
Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms for tumour resistance to chemotherapy.
Pan ST; Li ZL; He ZX; Qiu JX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):723-37. PubMed ID: 27097837
[TBL] [Abstract][Full Text] [Related]
9. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
10. Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.
Stark M; Assaraf YG
Oncotarget; 2017 Jul; 8(30):49973-49987. PubMed ID: 28637003
[TBL] [Abstract][Full Text] [Related]
11. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.
Thomas H; Coley HM
Cancer Control; 2003; 10(2):159-65. PubMed ID: 12712010
[TBL] [Abstract][Full Text] [Related]
12. The role of P-glycoprotein in drug resistance in multiple myeloma.
Abraham J; Salama NN; Azab AK
Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
[TBL] [Abstract][Full Text] [Related]
13. Curcumin as chemosensitizer.
Limtrakul P
Adv Exp Med Biol; 2007; 595():269-300. PubMed ID: 17569216
[TBL] [Abstract][Full Text] [Related]
14. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
15. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells.
Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ
Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901
[TBL] [Abstract][Full Text] [Related]
16. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
Nobili S; Landini I; Mazzei T; Mini E
Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
[TBL] [Abstract][Full Text] [Related]
17. Microparticles and their emerging role in cancer multidrug resistance.
Gong J; Jaiswal R; Mathys JM; Combes V; Grau GE; Bebawy M
Cancer Treat Rev; 2012 May; 38(3):226-34. PubMed ID: 21757296
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressors as multidrug resistance reversal agents.
Morjani H; Madoulet C
Methods Mol Biol; 2010; 596():433-46. PubMed ID: 19949935
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
Cascorbi I; Haenisch S
Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
[TBL] [Abstract][Full Text] [Related]
20. Clinical reversal of drug resistance.
Goldstein LJ
Curr Probl Cancer; 1995; 19(2):65-124. PubMed ID: 7600845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
